Exelixis, Inc.
EXEL
Rankning i aktier
#1415
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer,... Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
Aktiekurs
$62.33
Marknadsvärde
$15.67B
Förändring (1 dag)
0.16%
Förändring (1 år)
58.80%
Land
US
Handel Exelixis, Inc. (EXEL)
Kategori
Healthcare
Rörelsemarginal för Exelixis, Inc. (EXEL)
Rörelsemarginal per October 2026 TTM: 39.88%
Enligt de senaste finansiella rapporterna och aktiekursen för Exelixis, Inc. är företagets nuvarande rörelsemarginal (TTM) 39.88%. Vid slutet av 2025 var rörelsemarginalen 27.88%.
Historik för rörelsemarginal för Exelixis, Inc. från 2000 till 2026
Rörelsemarginal vid slutet av varje år
| År | Rörelsemarginal | Ändra |
|---|---|---|
| 2026 (TTM) | 39.88% | 43.04% |
| 2025 | 27.88% | 198.50% |
| 2023 | 9.34% | -25.34% |
| 2022 | 12.51% | -37.39% |
| 2021 | 19.98% | -47.67% |
| 2020 | 38.18% | -25.72% |
| 2018 | 51.40% | 40.17% |
| 2017 | 36.67% | -349.63% |
| 2016 | -14.69% | -98.36% |
| 2014 | -893.86% | 39.55% |
| 2013 | -640.54% | 148.24% |
| 2012 | -258.03% | -934.78% |
| 2011 | 30.91% | -162.58% |
| 2010 | -49.39% | -67.54% |
| 2009 | -152.14% | 9.93% |
| 2007 | -138.40% | 7.74% |
| 2006 | -128.46% | 3.81% |
| 2005 | -123.74% | -51.62% |
| 2004 | -255.79% | 36.95% |
| 2003 | -186.77% | -5.74% |
| 2002 | -198.15% | 7.88% |
| 2001 | -183.67% | 6.09% |
| 2000 | -173.12% | 0.00% |
Rörelsemarginal för liknande företag eller konkurrenter
| Företag | Rörelsemarginal | Skillnad i rörelsemarginal | Land |
|---|---|---|---|
| 38.59% | -99.03% |
US
|
|
| -149.01% | -103.74% |
US
|
|
| 25.57% | -99.36% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.28% |
NL
|
Vad är ett företags Rörelsemarginal?
Rörelsemarginal är en viktig indikator för att bedöma ett företags lönsamhet. Högre Rörelsemarginals är generellt bättre eftersom de visar att ett företag kan sälja sina produkter eller tjänster för betydligt mer än produktionskostnaden. Rörelsemarginal beräknas genom att dividera företagets vinst med dess intäkter.